1. Scrip

Dermira Ends Acne Program After Phase III Failure, Tries To Keep Focus On Hyperhidrosis Drug

 
• By Mandy Jackson

FDA approval for DRM04 in hyperhidrosis is expected at the end of June, but Phase III data for DRM01 in acne was the main event for investors. CEO Tom Wiggans said Dermira will try to understand what went wrong, while staying focused on DRM04 commercialization and lebrikizumab in Phase IIb.

Acne on face

Dermira Inc. Chairman and CEO Tom Wiggans did not pull any punches when talking about negative Phase III results for acne candidate olumacostat glaseratil (DRM01) March 5, instead being very upfront that the CLAREOS-1 and CLAREOS-2 studies failed and did not merit continued development of the drug.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Dermatological

More from Therapy Areas